ABSTRACT
Background Diagnostic errors are a global health priority and a common cause of preventable harm. There is limited data available for the prevalence of misdiagnosis in pediatric acute-care settings. Respiratory illnesses, which are particularly challenging to diagnose, are the most frequent reason for presentation to pediatric emergency departments.
Objective To determine the diagnostic error rate of acute childhood respiratory diseases in emergency departments.
Methods Prospective, multicenter, single-blinded, diagnostic accuracy study in two well-resourced pediatric emergency departments in a large Australian city. Between September 2016 and August 2018, a convenience sample of children aged 29 days to 12 years who presented with respiratory symptoms was enrolled. The emergency department discharge diagnoses were reported by clinicians based upon standard clinical diagnostic definitions. These diagnoses were compared against consensus diagnoses given by an expert panel of pediatric specialists using standardized disease definitions after they reviewed all medical records.
Results For 620 participants, the positive and negative percent agreement (%, [95% CI]) of the emergency department compared with the expert panel diagnoses were generally poor: isolated upper respiratory tract disease (61.4 [51.2, 70.9], 90.9 [88.1, 93.3]), croup (75.6 [64.9, 84.4], 97.9 [96.2, 98.9]), lower respiratory tract disease (86.4 [83.1, 89.6], 92.9 [87.7, 96.4]), bronchiolitis (66.9 [58.6, 74.5], 94.3 [80.8, 99.3]), asthma/reactive airway disease (91.0 [85.8, 94.8], 93.0 [90.1, 95.3]), clinical pneumonia (62·9 [49·7, 74·8], 95·0 [92·8, 96·7]), focal (consolidative) pneumonia (54·8 [38·7, 70·2], 86.2 [79.3, 91.5]). Only 59% of chest x-rays with consolidation were correctly identified. Between 6.9% and 14.5% of children were inappropriately prescribed based on their eventual diagnosis.
Conclusion In well-resourced emergency departments, we have identified a previously unrecognized high diagnostic error rate for acute childhood respiratory disorders, particularly in pneumonia and bronchiolitis. These errors lead to the potential of avoidable harm and the administration of inappropriate treatment.
Competing Interest Statement
Conflict of Interest Disclosures: Ms Bear received payment for statistical analysis. Dr Porter and Prof. Abeyratne are members of the Scientific Advisory Board, and shareholders of ResApp Health, an Australian company which provided funds for research assistant salaries. Ms Choveaux is also a shareholder in ResApp Health. Ms Brisbane, Dr Tan and Prof Della declare no COI. Funding/Support: The trial was supported by ResApp Health, research assistant salaries; Joondalup Health Campus, in-kind office facilities and PHI research group (non-profit), research staff. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Clinical Trial
ANZCTR: 12618001521213
Clinical Protocols
http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375939&isClinicalTrial=False
Funding Statement
Funding/Support: The trial was supported by ResApp Health, research assistant salaries; Joondalup Health Campus, in-kind office facilities and PHI research group (non-profit), research staff. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval to conduct the study was granted by the Human Research Ethics Committees of Ramsay Health Care WA|SA (Reference 1501) and the Child and Adolescent Health Service of Western Australia (Reference 2015030EP).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets supporting the conclusion of this article are available on reasonable request from PP after reciprocal ethical approval has been obtained. The cough recordings are not available but will be uploaded as an educational tool at the conclusion of the Breathe Easy development program in 2022.
